ライフサイエンスコーパス: gastric bypass

1 s standard Roux-en-Y gastric bypass surgery (gastric bypass).

2 pertension, and dyslipidemia after Roux-en-Y gastric bypass.

3 t and of adult controls undergoing Roux-en-Y gastric bypass.

4 ustable gastric banding to 76% for Roux-en-Y gastric bypass.

5 ation of the common channel following distal gastric bypass.

6 and hemoglobin A1c were greater after distal gastric bypass.

7 l comorbidities at 1 year after laparoscopic gastric bypass.

8 or older, and 8681 (98.5%) were treated with gastric bypass.

9 ns in short-term outcomes after laparoscopic gastric bypass.

10 loose stools were more frequent after distal gastric bypass.

11 pital admissions compared with patients with gastric bypass.

12 greater after duodenal switch compared with gastric bypass.

13 reduced after duodenal switch compared with gastric bypass.

14 y developed for bariatric patients requiring gastric bypass.

15 mbination of both methods, such as Roux-en-Y gastric bypass.

16 1 activity contributes to hypoglycemia after gastric bypass.

17 heir association with 30-day mortality after gastric bypass.

18 d as primary goal the changes in HDL-C after gastric bypass.

19 55,213, P = 0.003), than patients undergoing gastric bypass.

20 surgical hospital burden after laparoscopic gastric bypass.

21 plication rates after laparoscopic Roux-en-Y gastric bypass.

22 ion, 0.089 in colorectal resection, 0.085 in gastric bypass, 0.072 in cholecystectomy, and 0.060 in i

23 Bariatric procedures, which included 74% gastric bypass, 15% sleeve gastrectomy, 10% adjustable g

24 Patients undergoing Roux-en-Y gastric bypass (161 participants) or sleeve gastrectomy

25 d with a greater BMI reduction than standard gastric bypass 2 years after surgery.

26 F type occurred in 71% of patients following gastric bypass, 56% of patients who underwent sleeve gas

27 Gastric bypass (6.56 kg/mo) and sleeve gastrectomy (6.29

28 luded laparoscopic gastric banding (n=1053), gastric bypass (795), and sleeve gastrectomy (317), with

29 cedure for mouse and rat models of Roux-en-Y gastric bypass (80-90 min operative time) and sleeve gas

30 -GB), 7 patients who were asymptomatic after gastric bypass (A-GB), and 8 healthy control subjects un

31 The greatest effect size was observed for gastric bypass (adjusted RR, 43.1; 95% CI, 19.7-94.5), f

32 Interventions: Standard gastric bypass (alimentary limb, 150 cm) and distal gast

33 Eight (42%) patients who underwent gastric bypass and 13 (68%) patients who underwent bilio

34 was 17.8 (95% CI, 16.9-18.6) after standard gastric bypass and 17.2 (95% CI, 16.3-18.0) after distal

35 78% women): 1513 who had undergone Roux-en-Y gastric bypass and 509 who had undergone laparoscopic ad

36 1.0-16.1) and 22.1 (95% CI, 19.5-24.7) after gastric bypass and duodenal switch, respectively.

37 verse outcome rates were similar for primary gastric bypass and for procedures following failed adjus

38 is in patients undergoing bariatric surgery (gastric bypass and gastric banding).

39 0.23-0.86) and 1.18 (95% CI, 0.12-11.49) for gastric bypass and gastric banding, respectively.

40 identified 12364 and 1071 patients receiving gastric bypass and gastric banding, respectively.

41 0.12-0.71) and 0.53 (95% CI, 0.08-3.56) for gastric bypass and gastric banding, respectively.

42 0.33-0.81) and 1.23 (95% CI, 0.40-3.75) for gastric bypass and gastric banding, respectively.

43 Laparoscopic gastric bypass and laparoscopic duodenal switch.

44 omparison between 30-day outcomes of primary gastric bypass and procedures following failed adjustabl

45 Gastric bypass and sleeve gastrectomy have a greater eff

46 ciation between metabolic surgery (Roux-en-Y gastric bypass and sleeve gastrectomy) and major adverse

47 of the two most common bariatric procedures, gastric bypass and sleeve gastrectomy, on remission of d

48 ts who have undergone laparoscopic Roux-en-Y gastric bypass and to develop decision tree models to op

49 lusively open operations in 1993 (n = 8,631; gastric bypass and vertical banded gastroplasty, 49% eac

50 Bariatric surgeries, such as Roux-en-Y gastric bypass and vertical sleeve gastrectomy, produce

51 years, changes from baseline observed in the gastric-bypass and sleeve-gastrectomy groups were superi

52 tric Surgery (85 women underwent a Roux-en-Y gastric bypass, and 21 women underwent laparoscopic adju

53 er after distal gastric bypass than standard gastric bypass, and between-group differences were 19 mg

54 , 25 to 30) among participants who underwent gastric bypass, and by 26% (95% CI, 22 to 30) among thos

55 al patients (cholecystectomy, hernia repair, gastric bypass, and hysterectomy) who developed perioper

56 ss and 17.2 (95% CI, 16.3-18.0) after distal gastric bypass, and the mean between-group difference wa

57 rior studies comparing sleeve gastrectomy to gastric bypass are limited by low sample size (in random

58 The use of gastric bypass as the preferred bariatric procedure for

59 rs) with severe obesity undergoing Roux-en-Y gastric bypass at three specialised paediatric obesity t

60 ery group (N = 2007, per-protocol) underwent gastric bypass, banding or vertical banded gastroplasty,

61 ndergoing primary or revisional laparoscopic gastric bypass between January 1, 2004, and June 30, 201

62 Danish patients undergoing laparoscopic gastric bypass (BMI >35-50) from January 1, 2005 to Dece

63 ed (0.24, 95% CI 0.14-0.41, p < 0.001) after gastric bypass but not after gastric banding.

64 Hypoglycemia after gastric bypass can be corrected by administration of a G

65 c banding, sleeve gastrectomy, and Roux-en Y gastric bypass) can produce remarkable health improvemen

66 n BMI, 6.4 +/- 0.7) than those who underwent gastric bypass (change in BMI, 14.0 +/- 0.5) (P < .0001)

67 atric surgery (sleeve gastrectomy, Roux-en-Y gastric bypass), colorectal surgery (colectomy, proctect

68 bypass (alimentary limb, 150 cm) and distal gastric bypass (common channel, 150 cm), both with a bil

69 cantly greater in subjects who had undergone gastric bypass compared to the controls and in the H-GB

70 nificantly higher in the first 5 years after gastric bypass compared with a matched nonsurgical refer

71 and 22 of 48 (45.8%) patients randomized to gastric bypass, considering office and 24-hour ambulator

72 ely 11 % of patients who underwent Roux-en-Y gastric bypass develop symptomatic gallstone disease.

73 nt of SCFA release, latter was 40-45% in the gastric-bypassed emulsions and 30-35% in the sequentiall

74 2013 with the terms "bariatric filter" and "gastric bypass filter." Two investigators independently

75 people aged 13-21 years underwent Roux-en-Y gastric bypass for clinically severe obesity at a paedia

76 investigate whether the benefits and risk of gastric bypass for type 2 diabetes can be balanced.

77 Data on 22,327 patients undergoing primary gastric bypass from January 1, 2008, to June 30, 2012, w

78 data from 24,186 SG cases as well as 12,888 gastric bypass (GBP) cases.

79 ors for developing marginal ulcer (MU) after gastric bypass (GBP) surgery for obesity.

80 Gastric bypass (GBP) surgery, one of the most common bar

81 In all years, laparoscopic Roux-en-Y gastric bypass generated the highest number of wRVUs (wR

82 ssure occurred in 41 of 49 patients from the gastric bypass group (83.7%) compared with 6 of 47 patie

83 ore nutritional deficiencies occurred in the gastric bypass group (mainly deficiencies in iron, album

84 Significantly more participants in the gastric bypass group achieved the composite triple endpo

85 surgical patients (seven [37%] of 19 in the gastric bypass group and 12 [63%] of 19 in the bilipancr

86 lly important adverse events occurred in the gastric bypass group and 25 in the lifestyle and medical

87 p compared with only one complication in the gastric bypass group and no complications in the biliopa

88 Eleven patients (22.4%) from the gastric bypass group and none in the control group were

89 atients who achieved 2 year remission in the gastric bypass group and seven (37%) of the 19 patients

90 Across both years of the study, the gastric bypass group had seven serious falls with five f

91 diabetes remission rates were higher in the gastric bypass group than in the sleeve gastrectomy grou

92 el adjusted for site, the event rate for the gastric bypass group was non-significantly higher than t

93 Weight loss was the greatest in the gastric bypass group with a mean percentage weight loss

94 In the gastric bypass group, ten of 54 participants had early c

95 e and medical management group, eight in the gastric bypass group]).

96 group, as compared with 38% of those in the gastric-bypass group (P<0.001) and 24% of those in the s

97 eline, with reductions of 24.5+/-9.1% in the gastric-bypass group and 21.1+/-8.9% in the sleeve-gastr

98 e patients with recurrent hypoglycemia after gastric bypass (H-GB), 7 patients who were asymptomatic

99 Adolescents and adults who underwent gastric bypass had marked weight loss that was similar i

100 nts with severe obesity undergoing Roux-en-Y gastric bypass had substantial weight loss over 5 years,

101 Several studies have shown that gastric bypass has good effect on diabetes, at least in

102 at in people with type 2 diabetes, Roux-en-Y gastric bypass has therapeutic effects on metabolic func

103 s used currently, the sleeve gastrectomy and gastric bypass, have similar effects on weight loss and

104 at both procedures were safe, with Roux-en-Y gastric bypass having higher weight loss and follow-up r

105 ar percent weight change following Roux-en-Y gastric bypass, ie, weekly self-weighing, continuing to

106 We evaluated the health effects of Roux-en-Y gastric bypass in a cohort of adolescents (161 patients

107 e long-term (>5 years) outcomes of Roux-en-Y gastric bypass in a cohort of young adults who had under

108 dictor of diabetes remission after Roux-en-Y gastric bypass in obesity.

109 safety of standard gastric bypass vs distal gastric bypass in patients with a BMI of 50 to 60.

110 y, 2007, 74 young people underwent Roux-en-Y gastric bypass in the FABS study.

111 162,969; 69.8% sleeve gastrectomy and 27.8% gastric bypass) in 2016.

112 olescents and of adults undergoing Roux-en-Y gastric bypass, in the Adolescent Morbid Obesity Surgery

113 Complications after Roux-en-Y gastric bypass include anastomotic leaks and strictures,

114 Roux-en-Y gastric bypass induced significantly greater weight loss

115 A Roux-en-Y gastric bypass is the procedure of choice when GERD and

116 res performed include laparoscopic Roux-en-Y gastric bypass, laparoscopic adjustable gastric banding,

117 pic Roux-en-Y gastric bypass, open Roux-en-Y gastric bypass, laparoscopic gastric band placement, or

118 ectomy (LSG) compared to laparoscopic Roux-Y gastric bypass (LRYGB) after failed laparoscopic adjusta

119 ngitudinal Database) for 51,788 laparoscopic gastric bypass (LRYGB) procedures performed between 2007

120 h of stay (LOS) after laparoscopic Roux-en-Y gastric bypass (LRYGB) should be 1 day to improve resour

121 st as often in Europe as laparoscopic Roux-Y-Gastric Bypass (LRYGB).

122 Following standard gastric bypass, many of these patients still have a BMI

123 to the study, of whom 81 underwent Roux-en-Y gastric bypass (mean age 16.5 years [SD 1.2], bodyweight

124 Factors significantly associated with 30-day gastric bypass mortality included increasing body mass i

125 ty Surgery Registry, 509 patients (Roux-en-Y gastric bypass n=465; sleeve gastrectomy n=44) could be

126 medication), remission rates were 38.2% for gastric bypass ( n = 808) and 17.4% for gastric band (n

127 Roux-en-Y gastric bypass (n = 161), sleeve gastrectomy (n = 67), o

128 were randomly assigned and operated on with gastric bypass (n = 31) and duodenal switch (n = 29).

129 size-weighted remission rates were 66.7% for gastric bypass (n = 428) and 28.6% for gastric band (n =

130 ither medical treatment (n=20) or surgery by gastric bypass (n=20) or biliopancreatic diversion (n=20

131 ients were enrolled and randomly assigned to gastric bypass (n=54) or sleeve gastrectomy (n=55).

132 agement alone (n=60) or with the addition of gastric bypass (n=60).

133 ity and who underwent laparoscopic Roux-en-Y gastric bypass, open Roux-en-Y gastric bypass, laparosco

134 173 patients undergoing primary laparoscopic gastric bypass operation for morbid obesity between May

135 Adults having had a laparoscopic Roux-en-Y gastric bypass or a laparoscopic vertical sleeve gastrec

136 er medical treatment or surgery by Roux-en-Y gastric bypass or biliopancreatic diversion.

137 All Danish citizens who received gastric bypass or gastric banding between January 1, 199

138 sity were randomly assigned (1:1) to receive gastric bypass or sleeve gastrectomy (the Oseberg study)

139 ion to another weight loss procedure such as gastric bypass or sleeve gastrectomy in a single procedu

140 tive patients scheduled to undergo Roux-en-Y gastric bypass or sleeve gastrectomy in three bariatric

141 efits, bariatric surgery and, in particular, gastric bypass or sleeve gastrectomy may be considered a

142 on to a different bariatric procedure (eg, a gastric bypass or sleeve gastrectomy).

143 or intensive medical therapy plus Roux-en-Y gastric bypass or sleeve gastrectomy.

144 ymptomatic gallstone disease after Roux-en-Y gastric bypass or sleeve gastrectomy.

145 enrolled adults who had undergone Roux-en-Y gastric bypass or vertical sleeve gastrectomy and had pe

146 Patients who had a sleeve gastrectomy, gastric bypass, or duodenal switch were more likely to a

147 Compared to gastric bypass, other types of bariatric surgery had low

148 persistent NASH (30.4% vs 7.6% of those with gastric bypass; P = .015).

149 e, and any type of cardiovascular event than gastric bypass patients.

150 Patients were randomized to Roux-en-Y gastric bypass plus medical therapy or medical therapy a

151 we found that bariatric surgery, especially gastric bypass, prior to pregnancy was associated with i

152 years, operated with a primary laparoscopic gastric bypass procedure from 2010 until 2015 were ident

153 is low, psychiatric disorders, male sex, and gastric bypass procedure seem to increase the risk of su

154 atients who underwent laparoscopic Roux-en-Y gastric bypass procedure, in which comprehensive video d

155 all bowel obstruction after the laparoscopic gastric bypass procedure.

156 aparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass procedures between 2017 and 2018 were ide

157 ample of consecutive 120 patients undergoing gastric bypass procedures, a median of 12 events [interq

158 Roux-en-Y Gastric Bypass remains an excellent and durable operatio

159 In this nationwide study, gastric bypass resulted in large improvements in obesity

160 Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) accoun

161 the use and short-term outcome of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) in Swe

162 aste-induced brain responses after Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (V

163 (2)) is bariatric surgery, namely, Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy.

164 id glycemic improvements following Roux-en-Y gastric bypass (RYGB) are frequently attributed to the e

165 pment and ultimate remission after Roux-en-Y gastric bypass (RYGB) are not fully understood.

166 The antidiabetes effects of Roux-en-Y gastric bypass (RYGB) are well-known, but the underlying

167 veness and long-term durability of Roux-en-Y Gastric Bypass (RYGB) at an accredited center.

168 After Roux-en-Y gastric bypass (RYGB) chronic abdominal pain is common,

169 l cohort of veterans who underwent Roux-en-Y gastric bypass (RYGB) compared with nonsurgical matches

170 provement in type 2 diabetes after Roux-en-Y gastric bypass (RYGB) has been attributed partly to weig

171 isional laparoscopic surgery after Roux-en-Y gastric bypass (RYGB) has been linked to substantial com

172 tprandial glucose metabolism after Roux-en-Y gastric bypass (RYGB) has been the subject of uncertaint

173 Roux-en-Y gastric bypass (RYGB) improves glycemic control within d

174 e to the early and late effects of Roux-en-Y gastric bypass (RYGB) in 22 patients with T2D and 16 wit

175 metabolic and satiating effects to Roux-en-Y gastric bypass (RYGB) in rodent obesity models.

176 Sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) induce substantial weight loss and

177 Roux-en-Y gastric bypass (RYGB) involves exclusion of major parts

178 OUND AND AIMS: Hyperoxaluria after Roux-en-Y gastric bypass (RYGB) is generally attributed to fat mal

179 Roux-en-Y gastric bypass (RYGB) is highly effective in reversing o

180 The effect of a Roux-en-Y gastric bypass (RYGB) on body weight has been amply docu

181 of sleeve gastrectomy (SG) versus Roux-en-Y gastric bypass (RYGB) on liver function in bariatric pat

182 n pregnant women with a history of Roux-En-Y gastric bypass (RYGB) operation with a high risk of post

183 nt Procedural Terminology code for Roux-en-Y gastric bypass (RYGB) or adjustable gastric banding (AGB

184 in and physical function following Roux-en-Y gastric bypass (RYGB) or laparoscopic adjustable gastric

185 nversion of adjustable gastric band (AGB) to gastric bypass (RYGB) or sleeve gastrectomy (SG).

186 abetes mellitus were randomized to Roux-en-Y gastric bypass (RYGB) or to hypocaloric diet (HC diet) r

187 Bariatric procedures, such as Roux-en-Y gastric bypass (RYGB) or vertical sleeve gastrectomy (VS

188 Roux-en-Y gastric bypass (RYGB) produces substantial body weight (

189 Roux-en-Y gastric bypass (RYGB) reduces body weight and cardiovasc

190 drug use among patients undergoing Roux-en-Y gastric bypass (RYGB) surgery and a matched population-b

191 Both Roux-en-Y gastric bypass (RYGB) surgery and exercise can improve i

192 ms of metabolic improvements after Roux-en-Y gastric bypass (RYGB) surgery are not entirely clear.

193 n the prevalence of symptoms after Roux-en-Y gastric bypass (RYGB) surgery are sparse.

194 Roux-en-Y gastric bypass (RYGB) surgery causes profound weight los

195 ease and weight loss 5 years after Roux-en-Y gastric bypass (RYGB) surgery for morbid obesity in a la

196 e 2 diabetes (T2D) remission after Roux-en-Y gastric bypass (RYGB) surgery for patients taking insuli

197 pe 2 diabetes mellitus who undergo Roux-en-Y gastric bypass (RYGB) surgery or standard medical care r

198 t of type 2 diabetes after primary Roux-en-Y gastric bypass (RYGB) surgery, in patients with and with

199 d metabolism are upregulated after Roux-en-Y gastric bypass (RYGB) surgery, which contributes to a we

200 rs can be improved or prevented by Roux-en-Y gastric bypass (RYGB) surgery.

201 iation with weight loss induced by Roux-in-Y gastric bypass (RYGB) surgery.

202 ctors associated with mortality in Roux-en-Y gastric bypass (RYGB) surgery.

203 Roux-en-Y gastric bypass (RYGB) was associated with a higher rate

204 tical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB) with respect to diabetes treatment

205 e., a sleeve gastrectomy, proximal Roux-en Y gastric bypass (RYGB), and distal RYGB].

206 identified patients who underwent Roux-en-Y gastric bypass (RYGB), cholecystectomy, partial colectom

207 Roux-en-Y gastric bypass (RYGB), laparoscopic adjustable gastric b

208 n due to fasting, eating, obesity, Roux-en-Y gastric bypass (RYGB), vertical sleeve gastrectomy (VSG)

209 ore for internal hernia (IH) after Roux-en-Y gastric bypass (RYGB).

210 emia (PHH) is often reported after Roux-en-Y gastric bypass (RYGB).

211 rs and long-term weight loss after Roux-en-Y gastric bypass (RYGB).

212 poprotein A-IV (apoA-IV) rise with Roux-en-Y gastric bypass (RYGB).

213 systemic metabolomic profile after Roux-en-Y gastric bypass (RYGB).

214 loss and diabetes remission after Roux-en-Y gastric bypass (RYGB).

215 hol-related problems in women post-Roux-en-Y gastric bypass (RYGB).

216 tical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB).

217 nd HbA1c improvement compared with Roux-en-Y gastric bypass (RYGB).

218 ndial hypoglycemia is a risk after Roux-en-Y gastric bypass (RYGB).

219 e markers for T2DM remission after Roux-en-Y gastric bypass (RYGB).

220 or 2 years or surgical treatments (Roux-en-Y gastric bypass [RYGB] or laparoscopic adjustable gastric

221 he beneficial effect of bariatric (Roux-en-Y gastric bypass [RYGB]) surgery on insulin resistance.

222 Roux-en-Y gastric bypass (RYGBP) and sleeve gastrectomy (SG) have

223 Long-term health maintenance after Roux-en-Y gastric bypass should focus on adherence to dietary supp

224 ly more common in sleeve gastrectomy than in gastric bypass (sleeve 0.6%, bypass 0.4%, P = 0.009).

225 e for bariatric surgery, including Roux-en-Y gastric bypass, sleeve gastrectomy, or adjustable gastri

226 type of surgery (gastric banding, Roux-en-Y gastric bypass, sleeve gastrectomy, or other/unknown).

227 t to body weight (-23%, -19%, and -5% in the gastric-bypass, sleeve-gastrectomy, and medical-therapy

228 The gastric bypass subset was composed of 9480 (76.7%) women

229 were obtained from obese individuals during gastric bypass surgeries [ n = 16; body mass index: 44.8

230 d medical management plus standard Roux-en-Y gastric bypass surgery (gastric bypass).

231 Gastric bypass surgery (GBP) promotes early improvements

232 on for depression and death by suicide after gastric bypass surgery (GBP).

233 all bowel obstruction following laparoscopic gastric bypass surgery (incidence rates 46.5, 95% CI 38.

234 ve treatment for morbid obesity is Roux-en-Y gastric bypass surgery (RYGB), which results in rapid re

235 d without T2D (n = 9) subjected to Roux-en-Y gastric bypass surgery (RYGB).

236 Roux-en-Y gastric bypass surgery (RYGBP), the most commonly perfor

237 A cohort of 7925 patients undergoing gastric bypass surgery and 7925 group-matched, severely

238 e 2 diabetes mellitus-1 managed by Roux-en-Y gastric bypass surgery and a comparable group managed me

239 d type 2 diabetes, the metabolic benefits of gastric bypass surgery and diet were similar and were ap

240 ack of mortality benefit in those undergoing gastric bypass surgery at ages younger than 35 years pri

241 nts with type 2 diabetes mellitus undergoing gastric bypass surgery between January 2000 and July 200

242 Gastric bypass surgery can dramatically improve type 2 d

243 morbidly obese subjects undergoing Roux-en-Y gastric bypass surgery compared to lean controls undergo

244 r small bowel obstruction after laparoscopic gastric bypass surgery during the second and third trime

245 Patients undergoing gastric bypass surgery had a significantly lower age-rel

246 with the control group, the group undergoing gastric bypass surgery had a significantly reduced incid

247 The group undergoing gastric bypass surgery had greater percentage of excess

248 benefits and harms of laparoscopic Roux-en-Y gastric bypass surgery in patients defined by weight cla

249 Gastric bypass surgery is protective against mortality e

250 Gastric bypass surgery is the most effective treatment a

251 We hypothesized that gastric bypass surgery leads to a lower incidence of hea

252 Gastric bypass surgery not only induces remission of pha

253 l in Boston, Massachusetts, and involved 770 gastric bypass surgery patients between January 1, 2007,

254 The 25 804 gastric bypass surgery patients had on average lost 18.8

255 INTERPRETATION: Roux-en-Y gastric bypass surgery resulted in substantial and durab

256 Patients undergoing gastric bypass surgery seen at a private surgical practi

257 eared long-term complication to laparoscopic gastric bypass surgery that may be more common during pr

258 between those undergoing and not undergoing gastric bypass surgery using HRs.

259 Gastric bypass surgery was associated with approximately

260 Gastric bypass surgery was associated with improved long

261 surgery, adjusted all-cause mortality after gastric bypass surgery was significantly lower for patie

262 a hospital cohort of individuals undergoing gastric bypass surgery, and DMGV levels fell in parallel

263 milar levels of endogenous GLP-1 occur after gastric bypass surgery, and mechanistic studies indicate

264 that after 10 years of follow-up, Roux-en-Y gastric bypass surgery, compared with nonsurgical medica

265 with diabetes remission following Roux-en-Y gastric bypass surgery, suggesting new therapeutic appro

266 Among the 7925 patients who underwent gastric bypass surgery, the mean (SD) age at surgery was

267 For laparoscopic gastric bypass surgery, we used empirical Bayes techniqu

268 ppear to be the greatest in those undergoing gastric bypass surgery.

269 5.6) years) weight loss following Roux-en-Y gastric bypass surgery.

270 ontributing to the control of diabetes after gastric bypass surgery.

271 for serious complications after laparoscopic gastric bypass surgery.

272 ntifying the molecular mechanisms underlying gastric bypass surgery.

273 tprandial glycemia excursions increase after gastric bypass surgery; this effect is even greater amon

274 x, 41.8 +/- 6.3 kg/m(2); 46 +/- 11 y) during gastric-bypass surgery.

275 d (approximately 18%) weight loss induced by gastric bypass (surgery group) or diet alone (diet group

276 patients who sought and underwent Roux-en-Y gastric bypass (surgery group), 417 patients who sought

277 were higher among patients who had undergone gastric bypass than controls and increased with administ

278 year Framingham risk score were lower in the gastric bypass than in the control group.

279 serious complication rates with laparoscopic gastric bypass than other measures.

280 rotein cholesterol were greater after distal gastric bypass than standard gastric bypass, and between

281 bservational, prospective study of Roux-en-Y gastric bypass that was conducted in the United States.

282 eve gastrectomy (VSG) has recently surpassed gastric bypass to become the most popular surgical inter

283 eatment risks 2 years after adding Roux-en-Y gastric bypass to intensive lifestyle and medical manage

284 The addition of gastric bypass to lifestyle and medical management in pa

285 d with 14 of 49 patients (29%) who underwent gastric bypass (unadjusted P=0.01, adjusted P=0.03, P=0.

286 gastrectomy had a superior safety profile to gastric bypass up to 2 years from surgery, even when acc

287 esection, pancreatic resection, laparoscopic gastric bypass, ventral hernia repair, abdominal aortic

288 Laparoscopic Roux-en-Y gastric bypass, vertical sleeve gastrectomy, and adjusta

289 o assess the efficacy and safety of standard gastric bypass vs distal gastric bypass in patients with

290 eighted percentage of excess weight loss for gastric bypass was 65.7% (n = 3544) vs 45.0% (n = 4109)

291 In this exploratory analysis, gastric bypass was associated with a lower risk of all c

292 Gastric bypass was associated with a significantly reduc

293 However, gastric bypass was associated with additional surgical i

294 Laparoscopic Roux-en-Y gastric bypass was consistently among the top 10 procedu

295 Gastric bypass was found to be superior to sleeve gastre

296 Conclusions and Relevance: Distal gastric bypass was not associated with a greater BMI red

297 d with greater weight regain after Roux-en-Y gastric bypass, which inform patient care to improve lon

298 e levels 5 years after surgery compared with gastric bypass while improvements in health-related qual

299 nts who had undergone laparoscopic Roux-en-Y gastric bypass with surgically confirmed IH (n = 76) and

300 adolescent surgical patients after Roux-en-Y gastric bypass with those of conservatively treated adol